News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Citizens has increased its price target for OptimizeRx (NASDAQ:OPRX) to $11.00 from $9.00, maintaining a Market Outperform rating. This adjustment is based on a stabilizing macro environment, the potential return of a large customer, and momentum in mid-tier biopharma. The new target reflects an …
OptimizeRx (OPRX) reported a significant revenue decline of 21% year-to-date and 30% in Q2 2026, primarily due to the wind-down of a low-margin managed service program and the loss of revenue from a key customer. Despite this, the company improved its gross margin by …
Stifel has lowered its price target for OptimizeRx (NASDAQ: OPRX) to $12 from $14, while maintaining a Buy rating, due to significant revenue headwinds. The company reported a 30% year-over-year revenue decline in Q2 2026, though adjusted earnings per share exceeded expectations. OptimizeRx reiterated …
OptimizeRx has announced significant finance leadership appointments, effective January 1, 2027, as part of its succession planning. Andy D’Silva will take over as Chief Financial Officer, succeeding Ed Stelmakh, who will transition to a Strategic Advisor role. Heather Favazza has been appointed Chief Accounting …
OptimizeRx Corp (OPRX) reported a 30% year-over-year revenue decrease in Q2 2026, reaching $20.5 million, with adjusted EBITDA falling to $4.1 million. Despite these revenue headwinds, the company exceeded consensus expectations, driven by strong growth in AI-enabled software and product innovations. OptimizeRx reaffirmed its …
OptimizeRx Corp. reported Q2 2026 adjusted earnings of $0.16 per share, surpassing the $0.10 consensus, and revenue of $20.5 million, above the $20.19 million expectation. Despite beating profit views, the stock slipped after hours due to a 30% year-over-year revenue decline and continued pressure …
OptimizeRx Corp. (OPRX) exceeded Q2 earnings and revenue estimates, reporting $0.16 per share against an expected $0.11, and revenues of $20.5 million, slightly above the consensus. Despite these positive results, the company's shares have underperformed the S&P 500 this year, with a Zacks Rank …
OptimizeRx announced its second-quarter 2026 financial results, reporting $20.5 million in revenue and a GAAP net loss of $(0.7) million. Despite a year-over-year revenue decline, the company exceeded consensus expectations for revenue and adjusted EBITDA, which stood at $4.9 million. OptimizeRx reaffirmed its fiscal …
OptimizeRx (Nasdaq: OPRX) announced a planned finance leadership transition with Andy D’Silva appointed as the new Chief Financial Officer and Heather Favazza as Chief Accounting Officer, both effective January 1, 2027. Current CFO Ed Stelmakh will continue in his role through December 31, 2026, …
OptimizeRx (OPRX) reported a 30% decrease in Q2 2026 revenue to $20.5 million and a GAAP net loss of $0.7 million, down from a net income of $1.5 million in Q2 2025. Despite the revenue decline and lower net revenue retention, the company reaffirmed …
OptimizeRx Corp (OPRX) is expected to release its Q2 2026 earnings soon, with consensus estimates predicting $20.20 million in revenue and an earnings per share of -$0.05. Despite recent declines in revenue and earnings estimates for 2026, analysts and GuruFocus see significant upside potential, …
OptimizeRx Corp (OPRX) is scheduled to report its Q2 2026 earnings on August 12, with analysts expecting revenue of $20.20 million and a loss of $0.05 per share. Despite recent downward revisions in full-year revenue estimates and a significant stock drop after its Q1 …
OptimizeRx Corp (OPRX) has an earnings forecast score of 8.67, ranking 26th in the Software & IT Services industry. Analysts project an average price target of $24.00, with a consensus "Buy" rating based on 6 analysts. The company's expected revenue for the next quarter …
This article provides current stock information for OptimizeRx Corp (OPRX), including its latest stock price, market capitalization, and P/E ratio. It indicates that more news and analysis for OPRX will be published soon.
Segall Bryant & Hamill LLC has invested $1.19 million in OptimizeRx Corp. (NASDAQ: OPRX), acquiring 188,704 shares, which gives them a 1.01% stake in the company. Institutional investors now collectively own 76.47% of OptimizeRx, which recently exceeded quarterly earnings and revenue expectations. Analysts generally …
StockInvest.us has upgraded OptimizeRx Corporation (OPRX) to a "Buy Candidate" with a technical score of 2.73, up from a "Hold." The stock price increased by 8.26% on the last trading day, reaching $6.55, and is forecasted to rise 16.87% over the next three months. …
This article analyzes the valuation of OptimizeRx Corp (OPRX) using key financial metrics. As of July 31, 2026, OPRX has a valuation score of 8.04, placing it 219th in the Software & IT Services industry, with a P/E ratio of 16.38. The article notes …
This article provides a risk assessment for OptimizeRx Corp (OPRX), highlighting its current risk score of 4.19 and its beta of 1.14 against the S&P 500. It details various risk metrics including volatility, maximum drawdown, and Sharpe Ratio over different periods. The assessment suggests …
This article provides a technical analysis of OptimizeRx Corp (OPRX), focusing on its current stock price momentum, support and resistance levels, and various technical indicators and moving averages. It notes that OPRX's current price momentum score is 3.51, and the stock is trading between …
BlackRock, Inc. has filed an amendment (Schedule 13G/A) disclosing its beneficial ownership in OptimizeRx Corp (OPRX). As of June 30, 2026, BlackRock's reporting business units beneficially owned 342,250 shares of OptimizeRx common stock, representing 1.8% of the class. BlackRock reports having sole voting and …
OptimizeRx will host a conference call on Wednesday, August 12, 2026, at 4:30 p.m. Eastern Time to discuss its financial results for the second quarter ended June 30, 2026. Financial results will be released via press release before the call, which will include a …
OptimizeRx (Nasdaq: OPRX) has announced it will host a conference call on Wednesday, August 12, 2026, at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2026. The results will be released in a press announcement prior to …
This article provides an overview of OptimizeRx (OPRX) market sentiment, focusing on analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from 11 analysts with an average price target of $13, and notes declining short interest and bullish options …
OptimizeRx Corp (OPRX) has a strong financial health score of 7.50, ranking 194th in the Software & IT Services industry. While its financial status is robust, operational efficiency is average, with recent quarterly revenue and net profit showing year-over-year decreases of 9.50% and 77.49% …
This article provides a comprehensive cash flow statement for OptimizeRx Corp (OPRX), detailing quarterly and annual data for operating, investing, and financing cash flows. It includes key financial metrics like net income, capital expenditures, and free cash flow, along with year-over-year percentage changes. The …
This article provides an overview of OptimizeRx Corp's (OPRX) dividend and stock split history. It notes that the company has not distributed any dividends over the past five years. The page displays key financial data for OptimizeRx Corp, including its market cap and P/E …
This article provides a detailed breakdown of the shareholder structure for OptimizeRx Corp (OPRX), including major individual and institutional holders and their respective proportions. It also details institutional shareholding trends over recent quarters, changes in specific institutional holdings, and lists related ETFs that include …
OptimizeRx Corp (OPRX) has an institutional shareholding score of 7.00, ranking 139th out of 485 in the Software & IT Services industry. The institutional shareholding proportion recently increased by 8.32% quarter-over-quarter to 82.46%. The largest institutional shareholder is Bill Nygren | OAKMX, holding 1.14M …
OptimizeRx Corp (OPRX) shows strong fundamentals and high growth potential, with its valuation deemed fairly valued within the Software & IT Services industry. Analysts have rated it a "Buy" with a target price of $12.40. While the stock has seen strong market performance, technical …
OptimizeRx Corp. (NASDAQ:OPRX) announced the appointment of Sarah Bast as Chief Marketing Officer. Bast brings over 20 years of pharmaceutical marketing experience, having previously served as Executive Vice President at Publicis Health Media and guided marketing strategy for major life sciences companies. In her …
OptimizeRx (Nasdaq: OPRX) has appointed Sarah Bast as its new Chief Marketing Officer, effective July 23, 2026. Bast brings over two decades of experience in pharmaceutical marketing, specializing in point of care media strategy, analytics, and optimization. In her new role, she will lead …
Search by ticker symbol or company name and select a result to open its chart.